MRTX1133

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

MRTX1133 is an investigational cancer drug designed to inhibit the KRAS G12D mutation, which is found in some cancers. It was evaluated in a Phase 1/2 trial for solid tumors, but the study was terminated in the first quarter of 2025. The drug is not approved for clinical use. Safety notes: exposure to skin or eyes can be harmful, and inhalation may irritate the respiratory system.